Novobiocin
 | |
| Klinički podaci | |
|---|---|
| Prodajno ime | Albamix, Albamycin, Cardelmycin, Cathocin |
| Drugs.com | Monografija |
| Način primene | Intravenozno |
| Farmakokinetički podaci | |
| Poluvreme eliminacije | 6 h |
| Identifikatori | |
| CAS broj | 303-81-1  Y |
| ATC kod | None |
| PubChem | CID 9346 |
| DrugBank | DB01051 Y |
| ChemSpider | 8981 Y |
| KEGG | C05080 Y |
| ChEMBL | CHEMBL36506 Y |
| Hemijski podaci | |
| Formula | C31H36N2O11 |
| Molarna masa | 612,624 |
SMILES
| |
InChI
| |
Novobiocin je organsko jedinjenje, koje sadrži 31 atom ugljenika i ima molekulsku masu od 612,624 Da.[1][2][3][4][5][6][7]
Osobine
| Osobina | Vrednost |
|---|---|
| Broj akceptora vodonika | 11 |
| Broj donora vodonika | 5 |
| Broj rotacionih veza | 9 |
| Particioni koeficijent[8] (ALogP) | 3,5 |
| Rastvorljivost[9] (logS, log(mol/L)) | -6,4 |
| Polarna površina[10] (PSA, Å2) | 196,1 |
Reference
- ^ Vickers AA, Chopra I, O'neill AJ: Intrinsic novobiocin resistance in Staphylococcus saprophyticus. Antimicrob Agents Chemother. 2007 Sep 17;. PMID 17876001
- ^ Burlison JA, Neckers L, Smith AB, Maxwell A, Blagg BS: Novobiocin: redesigning a DNA gyrase inhibitor for selective inhibition of hsp90. J Am Chem Soc. 2006 Dec 6;128(48):15529-36. PMID 17132020
- ^ Singh G, Jayanarayan KG, Dey CS: Novobiocin induces apoptosis-like cell death in topoisomerase II over-expressing arsenite resistant Leishmania donovani. Mol Biochem Parasitol. 2005 May;141(1):57-69. PMID 15811527
- ^ CORBIN EE, PRIGOT A: Novobiocin; absorption, diffusion, and excretion studies. Antibiot Annu. 1956-1957;:392-5. PMID 13425410
- ^ DAVID NA, BURGNER PR: Clinical effectiveness and safety of novobiocin. Antibiotic Med Clin Ther. 1956 Apr;2(4):219-29. PMID 13303117
- ^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709
. PMID 21059682. doi:10.1093/nar/gkq1126. - ^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958.
- ^ Ghose, A.K.; Viswanadhan V.N. & Wendoloski, J.J. (1998). „Prediction of Hydrophobic (Lipophilic) Properties of Small Organic Molecules Using Fragment Methods: An Analysis of AlogP and CLogP Methods”. J. Phys. Chem. A. 102: 3762—3772. doi:10.1021/jp980230o.
- ^ Tetko IV, Tanchuk VY, Kasheva TN, Villa AE (2001). „Estimation of Aqueous Solubility of Chemical Compounds Using E-State Indices”. Chem Inf. Comput. Sci. 41: 1488—1493. PMID 11749573. doi:10.1021/ci000392t.
- ^ Ertl P.; Rohde B.; Selzer P. (2000). „Fast calculation of molecular polar surface area as a sum of fragment based contributions and its application to the prediction of drug transport properties”. J. Med. Chem. 43: 3714—3717. PMID 11020286. doi:10.1021/jm000942e.
Literatura
- Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
- Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.
Spoljašnje veze
Portal Medicina 
Portal Hemija
Novobiocin na Vikimedijinoj ostavi.
- Novobiocin
- p
- r
- u
(inhibira
purinski metabolizam,
i tim putem inhibira
DNK i RNK sintezu)
| DR inhibitor | |||||||
|---|---|---|---|---|---|---|---|
| Sulfonamidi (DS inhibitor) |
| ||||||
| Drugi/negrupisani | |||||||
| Kombinacije |
topoizomeraze/
hinoloni/
(inhibiraju
DNK replikaciju)
| 1. generacija | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fluorohinoloni |
|
inhibitori
| Nitro- imidazol derivati | |
|---|---|
| Nitrofuran derivati |
| Rifamicinii/ RNK polimeraza |
|---|
| |||||
